Oxford Genetics receives £1m investment
The injection of capital follows an impressive year of growth for the company.
A leading biotechnology company with expertise in DNA design is set to benefit from a £1 millon investment to support its growth strategy and assist in the delivery of new services for cancer fighting gene therapy technologies.
Oxford Genetics has secured the financing from Mercia Technologies, which is making the investment as part of its focus on supporting the creation, funding and scaling of innovative technology businesses with high growth potential.
The injection of capital follows an impressive year of growth for Oxford Genetics, which recently announced its relocation to new, state-of-the-art facilities in Oxford Science Park. The move enables its team to access dedicated cell development suites and new technology capable of automating certain processes, allowing the DNA expert to scale its services in line with increasing customer demand.
Commenting on the investment, Dr Ryan Cawood, CEO at Oxford Genetics, said: “We are pleased to receive this investment from Mercia, which follows a period of sustained and exciting growth for Oxford Genetics. Our biotech business has grown significantly in the last year, and is now looking to reinforce its position as the world leader in DNA design, protein expression, and virus and cell line engineering.
“With Mercia’s capital and support, as well as the move to our new facilities, we are confident that we can continue to scale the business into a global provider of synthetic biology solutions.”
Oxford Genetics first received investment from Mercia in July 2015, after being identified as the next ‘Emerging Star’ from Mercia’s third party funds. Mercia Technologies now holds a 46% share in the company and this latest round of funding will enable Oxford Genetics to continue licensing its technologies within the rapidly expanding markets of cell and gene therapy.Dr Mark Payton, CEO of Mercia Technologies PLC, said: “Synthetic biology is a key sub-sector for Mercia and the Board was pleased to be able to make a further investment in Oxford Genetics as it moves to a “pivotal stage” of its DNA design development.
“We are confident that with our support Oxford Genetics will continue to scale becoming what we believe will be a global provider of synthetic biology solutions, in what is a very attractive and growing market.”Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.